Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Zura Bio to post earnings of ($0.17) per share for the quarter.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter. On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $1.54 on Thursday. The firm has a market capitalization of $105.30 million, a PE ratio of -2.91 and a beta of 0.08. Zura Bio has a 52-week low of $0.97 and a 52-week high of $6.35. The firm has a fifty day moving average of $1.27 and a 200 day moving average of $2.27.

Wall Street Analysts Forecast Growth

ZURA has been the topic of a number of research reports. Chardan Capital decreased their price objective on Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, March 26th. Guggenheim reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Zura Bio in a research note on Wednesday, March 26th. Oppenheimer reiterated an "outperform" rating and issued a $19.00 target price (down previously from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Finally, HC Wainwright restated a "buy" rating on shares of Zura Bio in a research report on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $14.67.

Hedge Funds Weigh In On Zura Bio

A hedge fund recently raised its position in Zura Bio stock. Bank of America Corp DE boosted its holdings in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 31.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,222 shares of the company's stock after purchasing an additional 9,966 shares during the period. Bank of America Corp DE owned about 0.06% of Zura Bio worth $103,000 at the end of the most recent reporting period. Institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.